Activin RIIA/ACVR2A mFc Chimera, Human/Cynomolgus
Activin RIIA/ACVR2A MFc Chimera, Human/Cynomolgus

Immobilized Human Activin A, No Tag at 1 μg/ml (100 μI/well) on the plate. Dose response curve for Activin RIIA/ACVR2A mFc Chimera, Human/Cynomolgus, mFc Tag with the EC50 of 5.6ng/ml determined by ELISA.

Activin RIIA/ACVR2A MFc Chimera, Human/Cynomolgus

The purity of Activin RIIA/ACVR2A mFc Chimera, Human/Cynomolgus is greater than 95% as determined by SEC-HPLC.

Activin RIIA/ACVR2A MFc Chimera, Human/Cynomolgus

Activin RIIA/ACVR2A mFc Chimera, Human/Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Activin RIIA/ACVR2A mFc Chimera, Human/Cynomolgus

Activin A receptor type 2A (ACVR2A) is a membrane receptor in the transforming growth factor- beta (TGF-β signaling pathway, which is involved in the regulation of cell proliferation, migration, and apoptosis. Loss of ACVR2A has an important role in cancer progression and distant metastasis and may serve as a prognostic marker in patients with colon cancer.
Z04987
¥31,712.00

Ask us a question
Product Introduction
Species Human/Cynomolgus
Protein Construction
Activin RIIA/ACVR2A (Ala20-Pro135)
Accession # P27037-1 (Human) / G7PKJ4 (Cynomolgus)		 mFc (IgG1)
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 39.07 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • Activin RIIA/ACVR2A MFc Chimera, Human/Cynomolgus
    • Activin RIIA/ACVR2A MFc Chimera, Human/Cynomolgus

    Immobilized Human Activin A, No Tag at 1 μg/ml (100 μI/well) on the plate. Dose response curve for Activin RIIA/ACVR2A mFc Chimera, Human/Cynomolgus, mFc Tag with the EC50 of 5.6ng/ml determined by ELISA.

  • Activin RIIA/ACVR2A MFc Chimera, Human/Cynomolgus
    • Activin RIIA/ACVR2A MFc Chimera, Human/Cynomolgus

    The purity of Activin RIIA/ACVR2A mFc Chimera, Human/Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • Activin RIIA/ACVR2A MFc Chimera, Human/Cynomolgus
    • Activin RIIA/ACVR2A MFc Chimera, Human/Cynomolgus

    Activin RIIA/ACVR2A mFc Chimera, Human/Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Activin A receptor type 2A (ACVR2A) is a membrane receptor in the transforming growth factor- beta (TGF-β signaling pathway, which is involved in the regulation of cell proliferation, migration, and apoptosis. Loss of ACVR2A has an important role in cancer progression and distant metastasis and may serve as a prognostic marker in patients with colon cancer.
Synonyms ACTR-IIA; ACTRIIA; ACVR2A; ACVR2

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.